NASDAQ:ALXN
Delisted
Alexion Pharmaceuticals Stock News
$182.50
+0 (+0%)
At Close: May 27, 2022
5 Biotech Acquisition Targets To Accumulate In 2024
01:05pm, Thursday, 21'st Dec 2023
Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provid
AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris
02:51am, Wednesday, 06'th Sep 2023
AstraZeneca PLC (LSE:AZN) said the US Food and Drug Administration (FDA) has responded to a request to expand the use of the drug Ultomiris by asking for a risk evaluation and mitigation strategy. In
AstraZeneca to pay US$775mln to settle Alexion patent dispute
05:15am, Thursday, 17'th Mar 2022
AstraZeneca PLC (LSE:AZN) is set to pay out US$775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation rela
AstraZeneca PLC boosted by Alexion acquisition; five newly-minted blockbusters join its medicine cabinet
02:45am, Thursday, 10'th Feb 2022
AstraZeneca PLC (LSE:AZN) said five new drugs had taken on blockbuster status last year generating over US$1bn in revenues each as delivered a strong financial performance, boosted by the US$39bn take
AstraZeneca's takeover of Alexion the highlight of a quieter quarter for mergers & acquisitions
05:12am, Tuesday, 07'th Dec 2021
AstraZeneca PLC (LSE:AZN)'s acquisition of Alexion Pharmaceuticals (NASDAQ:ALXN) Inc was the highlight of a third-quarter that saw UK companies splash out £32.8bn on acquisitions. Figures from the Of
Jeremy Grantham's Firm Profits From Wave of Acquisitions in 3rd Quarter
04:45pm, Friday, 12'th Nov 2021
Jeremy Grantham (Trades, Portfolio)'s GMO LLC recently disclosed its 13F portfolio updates for the third quarter of 2021, which ended on Sept. 30.
AstraZeneca eyes big jump in revenue after Alexion acquisition
05:07am, Thursday, 29'th Jul 2021
AstraZeneca PLC has announced higher full-year guidance to include the newly acquired Alexion, after the transaction was completed last week. The pharma giant expects total revenue to jump 21-22%, wit
AstraZeneca says Alexion receives recommendation to use rare blood disorder drug in kids
03:09am, Monday, 26'th Jul 2021
AstraZeneca PLC (LON:AZN) announced that Alexion's Ultomiris has been recommended for marketing authorisation in the EU for expanded use to include children and adolescents with paroxysmal nocturnal h
ALXN vs. TECH: Which Stock Is the Better Value Option?
01:09pm, Wednesday, 21'st Jul 2021
ALXN vs. TECH: Which Stock Is the Better Value Option?
Alexion's Ultomiris Sales Almost Doubles In 1H 2021 As $39B AstraZeneca Deal Looms
02:37pm, Tuesday, 20'th Jul 2021
Ultomiris, the successor to Alexion Pharmaceuticals Inc's (NASDAQ: ALXN) paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris, is on track for another blockbuster year. The drug posted $701 millio
AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?
07:01am, Saturday, 17'th Jul 2021
Probably so.
With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?
06:48am, Saturday, 17'th Jul 2021
With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21.
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.
04:19pm, Friday, 16'th Jul 2021
What did the stock market do today? It saw Moderna reach a major index, it saw Americans spending big, and it saw Biden targeting China.
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG Study
03:28pm, Friday, 16'th Jul 2021
Alexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal.
This Nasdaq Vaccine Stock Just Got a Big Boost -- and Another Nasdaq Vaccine Stock Deserves the Credit
12:29pm, Friday, 16'th Jul 2021
Find out why a big index move is so interesting for investors.
